Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery
- 1Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK
- 2Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7LD, UK
- 3Oxford Biomedica (UK) Limited, Windrush Court, Transport Way, Oxford OX4 6LT, UK
Abstract
Lentiviral vector (LVV)-mediated chimeric antigen receptor (CAR)-T cell therapy has transformed the landscape for blood cancer treatment through genetic modification of patients’ T cells. Yet, the complexity of the manufacturing process makes this therapy inaccessible for many patients. Systemic intravenous delivery of LVV is an attractive prospect not only for CAR-T therapeutics but also extends the potential benefit to inherited monogenic diseases. However, immunogenicity to LVV is a major hurdle to safe and efficacious gene delivery in vivo. Here, we categorize the immune responses into three main challenges: displacement of LVV from its intended target cells by components of the blood, inefficient transduction of target cells due to evolutionarily conserved viral detection and restriction, and clearance of the transduced cell population by the adaptive immune system. We review the progress toward in vivo delivery and the many approaches explored to circumvent immune barriers, from direct engineering of the LVV itself to pharmacological intervention. We report that while many approaches demonstrate improved efficacy, they often tackle only one aspect in isolation in a selected animal model. Therefore, we recommend researchers adopt a more holistic approach, testing a cocktail of strategies in a model that best recapitulates gene delivery to patients.
Related
- An inducible human LDLR transgenic mouse model for enhanced lentiviral gene delivery to murine immune cells
- Precision cooling assists electrical stimulation: Breaking selectivity barriers in nerve control
- CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
- Nanotechnology-based strategies for helminth control: drug delivery, green nanoparticles, mechanisms, and translational barriers.
- Barriers and enablers shaping kidney transplant care delivery: Insights from Iraqi pharmacists
BibTeX
@article{keating2026stealthy,
title = {{Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery}},
author = {Amy L. Keating and Robert C. Carlisle and Kyriacos A. Mitrophanous and Leonard W. Seymour and Kerry D. Fisher},
journal = {Molecular Therapy Advances},
year = {2026},
month = sep,
doi = {10.1016/j.omta.2026.201856},
url = {https://doi.org/10.1016/j.omta.2026.201856},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery
AU - Amy L. Keating
AU - Robert C. Carlisle
AU - Kyriacos A. Mitrophanous
AU - Leonard W. Seymour
AU - Kerry D. Fisher
PY - 2026
DA - 2026/09/29
JO - Molecular Therapy Advances
DO - 10.1016/j.omta.2026.201856
UR - https://doi.org/10.1016/j.omta.2026.201856
AB - Lentiviral vector (LVV)-mediated chimeric antigen receptor (CAR)-T cell therapy has transformed the landscape for blood cancer treatment through genetic modification of patients’ T cells. Yet, the complexity of the manufacturing process makes this therapy inaccessible for many patients. Systemic intravenous delivery of LVV is an attractive prospect not only for CAR-T therapeutics but also extends the potential benefit to inherited monogenic diseases. However, immunogenicity to LVV is a major hurdle to safe and efficacious gene delivery in vivo. Here, we categorize the immune responses into three main challenges: displacement of LVV from its intended target cells by components of the blood, inefficient transduction of target cells due to evolutionarily conserved viral detection and restriction, and clearance of the transduced cell population by the adaptive immune system. We review the progress toward in vivo delivery and the many approaches explored to circumvent immune barriers, from direct engineering of the LVV itself to pharmacological intervention. We report that while many approaches demonstrate improved efficacy, they often tackle only one aspect in isolation in a selected animal model. Therefore, we recommend researchers adopt a more holistic approach, testing a cocktail of strategies in a model that best recapitulates gene delivery to patients.
SN - 3117-387X
ER -